Skip to main content
Mezzion Pharma Co., Ltd. logo

Mezzion Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 140410 ISIN · KR7140410002 KO Manufacturing
Open in API
Filings indexed 218 across all filing types
Latest filing 2025-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 140410

About Mezzion Pharma Co., Ltd.

https://mezzion.com

Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare diseases. The company's primary efforts are concentrated on addressing the unmet medical needs of individuals with a Fontan circulation, a palliative surgical procedure for single-ventricle heart defects. Its lead drug candidate, udenafil, is being advanced as a potential first-to-market treatment to improve the physiology of the Fontan circulation. Mezzion is conducting late-stage clinical development, including a confirmatory Phase 3 trial (FUEL-2), to evaluate the therapy's efficacy in adolescent patients.

Recent filings

Filing Released Lang Actions
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the 1st quarter of 2025, submitted by Mezzion Co., Ltd. to the Financial Services Commission and the Korea Exchange. It contains detailed business information, financial data, and management discussions, which fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM) for the company '메지온' (Mezzion). It details the outcomes of agenda items such as financial statement approval, director appointments, and remuneration limits. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the official record of shareholder voting outcomes.
2025-03-28 Korean
사업보고서 (2024.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 23rd fiscal year (2024) of Mezzion Pharma Co., Ltd. It contains comprehensive information including company overview, history, capital structure, business operations, and financial data. This is a standard annual regulatory filing required by the Financial Supervisory Service (FSS) in South Korea, which corresponds to the 10-K category in the provided schema. FY 2024
2025-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from the Korean Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion, key financial data (assets, liabilities, revenue, profit/loss), and auditor information. While it contains financial data, it is a standard regulatory disclosure form used in Korea to announce the receipt and filing of the audit report, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2024
2025-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Mezzion. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and remuneration limits. It also includes detailed management information, such as board activity reports and business overviews, which are standard components of proxy materials sent to shareholders to solicit votes. Since this document serves as the official notice and information package for the AGM, it is classified as Proxy Solicitation & Information Statement.
2025-03-13 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by the company Mezzion. It outlines the date, location, and agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2025-03-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.